(Rac)-Centrolobol
(Rac)-Centrolobol is a racemic isomer of Centrolobol (HY-N3564). Centrolobol is a diarylheptane compound with antioxidant and anti-inflammatory properties, which exists in the fermented stems of Alnus sibirica. Centrolobol scavenges DPPH free radicals and inhibits the production of NO in LPS-stimulated immune cells. Centrolobol can be used in studies related to anti-inflammation and antioxidation.
For research use only. We do not sell to patients.
- CAS No.: 98119-94-9
- Formula: C19H24O3
- Molecular Weight:300.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Centrolobol (compound 12) inhibits nitric oxide production in LPS-stimulated RAW 264.7 cells, with an IC50 value of 27.77 μM[1].
Centrolobol inhibits the production of DPPH, with an IC50 value of 44.4 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 98119-94-9
-
Molecular Weight 300.39
-
Formula C19H24O3
-
SMILES
OC1=CC=C(CCCCC(CCC2=CC=C(C=C2)O)O)C=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(Rac)-Centrolobol Related Classifications
HY-N3564A Related Classifications
Powered by Bioz